spacer
home > ebr > spring 2019 > jewel biomarkers can be found by digging in the right mine
PUBLICATIONS
European Biopharmaceutical Review

Jewel Biomarkers Can Be Found By Digging in the Right Mine

Biomarkers can be fantastic diagnostic tools, especially for rare diseases (1:2,000 up to about 1:100,000) for which an accurate identification may even be lifesaving if identified early on. Literature and experts see biomarkers as cornerstones for the development of new therapeutic approaches.

The EMA and FDA are proponents of seeing the therapeutic effects achieved through biomarker-based ‘theragnostic’. Historically, surrogate biomarkers were accepted in the past (for example, haemoglobin A1c for diabetes). Nowadays, however, biomarkers closely linked to a sickness and potential therapeutic intervention are even more welcome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, Bioanalytical Consultant and founder of pharm-analyt Labor, has more than 100 publications in peer-reviewed journals (and more than 230 cumulative impact factor). He is the inventor of three patents for biomarkers in the area of rare LSDs (Gaucher, NP-C, and metachromatic leukodystrophy) which could be sold.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement